hrs4r
 I want to donate
Firma
RAFAEL FUENTES-RASPALL
Position
Investigador/a Post-doctoral – R2
Postdoctoral Researchers – R2

Projectes

Codi oficial: H2845SM6P Start date:01/01/2023 Data fi: 31/12/2024 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 24,000 €
Codi oficial: 6822ZB3KJ Start date:01/01/2023 Data fi: 31/12/2024 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 0 €

Publicacions

0

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 1017-1023 dx.doi.org/10.1007/s12094-022-03005-4

Jurado-Bruggeman, D, Munoz-Montplet, C, Hernandez, V, Saez, J, Fuentes-Raspall, R

Impact of the dose quantity used in MV photon optimization on dose distribution, robustness, and complexity

MEDICAL PHYSICS, 2022, 49, 648-665 dx.doi.org/10.1002/mp.15389

Muñoz-Montplet C, Fuentes-Raspall R, Jurado-Bruggeman D, Agramunt-Chaler S, Onsès-Segarra A, Buxó M

Dosimetric Impact of Acuros XB Dose-to-Water and Dose-to-Medium Reporting Modes on Lung Stereotactic Body Radiation Therapy and Its Dependency on Structure Composition

Advances in Radiation Oncology, 2021, 6, 100722-100722 dx.doi.org/10.1016/j.adro.2021.100722

Romera-Martínez I, Muñoz-Montplet C, Jurado-Bruggeman D, Onsès-Segarra A, Fuentes-Raspall R, Buxó M, Vilanova JC

A Novel Device for Deep-Inspiration Breath Hold (DIBH): Results from a Single-Institution Phase 2 Clinical Trial for Patients with Left-Sided Breast Cancer

Practical Radiation Oncology, 2020, 10, 290-297 dx.doi.org/10.1016/j.prro.2020.02.004

Fuentes-Raspall R, Solans M, Auñon-Sanz C, Saez M, Marcos-Gragera R

Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013)

CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20, 1628-1630 dx.doi.org/10.1007/s12094-018-1890-8

Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F, GLIOCAT Group

Pseudoprogression as an adverse event of glioblastoma therapy.

CANCER MEDICINE, 2017, 6, 2858-2866 dx.doi.org/10.1002/cam4.1242

Fuentes-Raspall R, Solans M, Roca-Barceló A, Vilardell L, Puigdemont M, Del Barco S, Comas R, García-Velasco A, Astudillo A, Carmona-Garcia MC, Marcos-Gragera R

Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013).

CANCER EPIDEMIOLOGY, 2017, 50, 1-8 dx.doi.org/10.1016/j.canep.2017.07.005

Formulari de contacte

About IDIBGI!

menu